Search
Prednisolone
go.drugbank.com/drugs/DB00860ApprovedInvestigationalVet approved[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Pegaptanib
go.drugbank.com/drugs/DB04895ApprovedWithdrawnPegaptanib was granted FDA approval on 17 September 2004.[L17903]
Ranibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigational[L41399] In August 2022, other biosimilars CIMERLI, RAIVISIO, and RANOPTO were approved by the FDA, EC, and Health Canada respectively.[L42625,L43513,L49141] … [A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO.
Pralsetinib
go.drugbank.com/drugs/DB15822ApprovedInvestigational[A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment
Mecasermin rinfabate
go.drugbank.com/drugs/DB14751ApprovedInvestigationalMecasermin rinfabate manufactured by Insmed Incorporated under the brand name Iplex was approved by the FDA in 2005[L5722].
Terconazole
go.drugbank.com/drugs/DB00251Approved[A178096] Terconazole was initially approved by the FDA in 1987. … [FDA label] This drug is available in cream and suppository forms and both have demonstrated high levels of safety, efficacy, and tolerability in clinical trials.
Oritavancin
go.drugbank.com/drugs/DB04911ApprovedInvestigational[A39384,A193482,L8492] On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. … [L32634] Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg.
Glyburide
go.drugbank.com/drugs/DB01016ApprovedInvestigational[A183617] Glyburide was granted FDA approval on 1 May 1984.[L8117] A formulation with metformin was granted FDA approval on on 31 July 2000.[L8120]
Dihydrostreptomycin
go.drugbank.com/drugs/DB11512ApprovedVet approvedWithdrawnThe FDA withdrew its approval for the use of all drug products containing dihydrostreptomycin sulfate.[L43942]
Brolucizumab
go.drugbank.com/drugs/DB14864ApprovedInvestigational[L9089] Brolucizumab was granted FDA approval in October 2019.[L9089]